The Vaccines Company

Vaccine Company Inc. is a clinical-stage biotechnology company focused on developing next-generation vaccines using a proprietary ferritin nanoparticle platform. The company's lead candidate, DCFHP-Alum, is a spike-functionalized ferritin nanoparticle vaccine currently in Phase 1 clinical trials for the prevention of COVID-19. In late 2024, the company received a $28 million grant from ARPA-H to advance its Project A-FAVE, which utilizes applied biotechnology for broad flavivirus antigen discovery and vaccine evaluation targeting West Nile, dengue, and Zika viruses. Led by former senior executives from Pfizer and the NIH, the company operates with a focus on pandemic preparedness and broad-spectrum viral protection.